Universität zu Köln

Fuchs, Frieder, Hof, Herbert, Hofmann, Sandra, Kurzai, Oliver, Meis, Jacques F. and Hamprecht, Axel ORCID: 0000-0003-1449-5780 (2021). Antifungal activity of nitroxoline against Candida auris isolates. Clin. Microbiol. Infect., 27 (11). OXFORD: ELSEVIER SCI LTD. ISSN 1469-0691

Full text not available from this repository.

Abstract

Objectives: To investigate the in vitro activity of nitroxoline against a molecularly characterized collection of clinical Candida auris isolates. Methods: Thirty-five clinical isolates of C. auris from diverse sources representing all five different C. auris clades were included in the study. Nitroxoline activity was assessed using broth microdilution. Additionally, susceptibility testing by disc diffusion was assessed on RPMI-1640 and Muller-Hinton agar plates. Minimal inhibitory concentrations of the antifungals fluconazole, voriconazole, amphotericin B and anidulafungin were determined. Results: Nitroxoline MICs ranged from 0.125 to 1 mg/L (MIC50/90 0.25/0.5 mg/L). Compared with amphotericin B (MIC >1 mg/L in 4/35 isolates), anidulafungin (MIC >0.06 mg/L in 26/35 isolates) and fluconazole (MIC >4 mg/L in 31/35 isolates), in vitro activity of nitroxoline was high. Isolates belonging to clade I had marginally lower nitroxoline MICs (range 0.125-0.5 mg/L, mean MIC 0.375 mg/L) compared with clade III (range 0.5-1 mg/L, mean MIC 0.7 mg/L; p 1/4 0.0094). The correlation of MIC and inhibition zones by disc diffusion was good when using RPMI-agar for disc diffusion, with a Pearson's correlation coefficient of-0.74 (95% CI-0.86 to-0.54). Conclusions: Nitroxoline has excellent in vitro activity against C. auris isolates, with MICs of 0.125-1 mg/L (for comparison, the EUCAST breakpoint for uncomplicated urinary tract infection with Escherichia coli is <= 16 mg/L). It is an approved, well-tolerated antimicrobial that achieves high urinary concentrations after oral administration and could be a useful treatment option in C. auris candiduria. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Fuchs, Frieder UNSPECIFIED UNSPECIFIED UNSPECIFIED Hof, Herbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Hofmann, Sandra UNSPECIFIED UNSPECIFIED UNSPECIFIED Kurzai, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Meis, Jacques F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hamprecht, Axel UNSPECIFIED orcid.org/0000-0003-1449-5780 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-594735
DOI:	10.1016/j.cmi.2021.06.035
Journal or Publication Title:	Clin. Microbiol. Infect.
Volume:	27
Number:	11
Date:	2021
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1469-0691
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Infectious Diseases; Microbiology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59473